A Phase 4 interventional study of Secretin (human synthetic) - ChiRhoClin in Exocrine Pancreatic Insufficiency and Chronic Pancreatitis, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Mayo Clinic · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Exocrine Pancreatic Insufficiency with a site in United States — 11 open to participants now, 13 under way, 1 of them phase 3. Exocrine Pancreatic Insufficiency · United States.
Among the 73 studies in Exocrine Pancreatic Insufficiency with a site in United States, this one is the 38th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 in phase 4, reaches primary completion later than 2 of the 12 other live ones, and was the 67th registered.
136 studies on the registry are indexed under Exocrine Pancreatic Insufficiency; 26 are open to participants now.
Browse Exocrine Pancreatic Insufficiency studies →11 of the 73 studies in Exocrine Pancreatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Digestive Care, Inc. · Sites in United States
Ages 7–50
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
Anna Evans Phillips · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Exocrine Pancreatic Insufficiency studies recruiting now, 12 (63%) set no upper age limit and 5 (26%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 20 · Phase 4 13
First in 1988; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 40 across 94 interventional studies indexed under Exocrine Pancreatic Insufficiency.
Median enrollment 31 across the 59 interventional studies, 128 across the 14 observational. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 73 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 1 study filed under Exocrine Pancreatic Insufficiency — fewer than ten, so there is no comparison to draw.
10 of the studies in Exocrine Pancreatic Insufficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06691893Phase 3Massachusetts General HospitalEvaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients | 2027-04-15 |
| NCT01851694University of PennsylvaniaBeta-cell Response to Incretin Hormones in Cystic Fibrosis | 2026-12 |
| NCT07285863Mayo ClinicA Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects | 2027-03 |
| NCT07554560Children's Hospital of PhiladelphiaNutrition Intervention for Pancreatic Cancer | 2027-04 |
| NCT07559175Aimmune Nestlé Health Science US R&D, LLCA Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. | 2027-06 |
Add all 10 to your calendar (.ics) → With an account.
Among the 73 studies in Exocrine Pancreatic Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants without pancreatic disease who are undergoing an endoscopic ultrasound for a non-pancreatic indication. Participants will be given a standard dose of intravenous human secretin (0.2 mcg/kg) during the endoscopic ultrasound. During this time, pancreatic fluid will be collected at 5 minutes, 10 minutes, 15 minutes, and 20 minutes after secretin administration.
Drug: Secretin (human synthetic) - ChiRhoClin
During endoscopic ultrasound (EUS), a dose of intravenous secretin (0.2 µg/kg) will be administered over the course of 1 minute to stimulate pancreatic ductal cells to secrete pancreas fluid. Duodenal fluid will be aspirated through the echoendoscope in 5 minute increments (5, 10, 15, and 20 minutes) after the secretin has been administered
Pancreatic Fluid Bicarbonate Composition
A primary outcome will be the bicarbonate level (milliequivalent per liter) in the pancreatic fluid collected.
Time frame: 5, 10, 15, and 20-minutes post-secretin administration
Pancreatic Fluid Sodium Composition
A primary outcome will be the sodium level (milliequivalent per liter) in the pancreatic fluid collected.
Time frame: 5, 10, 15, and 20-minutes post-secretin administration
Pancreatic Fluid Potassium Composition
A primary outcome will be the potassium level (milliequivalent per liter) in the pancreatic fluid collected.
Time frame: 5, 10, 15, and 20-minutes post-secretin administration
Pancreatic Fluid Chloride Composition
A primary outcome will be the chloride level (milliequivalent per liter) in the pancreatic fluid collected.
Time frame: 5, 10, 15, and 20-minutes post-secretin administration
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Exocrine Pancreatic Insufficiency →